- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01134380
Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment (GIANT)
Study Overview
Status
Detailed Description
All the STEMI patients treated by primary PCI (with stent implantation) within the 24 hours following the first chest pain can be included in the GIANT study. After the PCI, they'll receive DAT (Aspirin + Clopidogrel/Prasugrel).
Patients will then be genotyped to determine if they carry one of the CYP2C19 gene variants making them resistant or hyper responder to clopidogrel. The genetic profile of the patients will be communicated to the physician who took care of them so that he can (or not) adjust the thienopyridine treatment (increase of the clopidogrel dosage, switch to prasugrel or switch to clopidogrel). A treatment will be prescribed for 12 months as according to the European guidelines.
One year after the PCI, the patients will have to be available for a follow up visit. They'll be submitted to a VERIFY NOW P2Y12 protocol to determine whether they were compliant to their thienopyridine treatment. A clinical follow up will be also performed to evaluate the cardiovascular events.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Annecy, France
- Centre Hospitalier de la Région Annecienne
-
Colmar, France, 68003
- Hôpital Albert Schweitzer
-
Corbeil Essonnes, France
- Centre Hospitalier Sud Francilien
-
Haguenau, France
- Centre Hospitalier d'Haguenau
-
Lyon, France, 69007
- Centre Hospitalier Saint Joseph Et Saint Luc
-
Massy, France, 91300
- Hôpital Privé Jacques Cartier
-
Metz, France
- Hôpital Bon Secours
-
Montpellier, France
- Hopital Arnaud de Villeneuve
-
Nîmes, France
- Centre Hospitalier Universitaire Caremeau
-
Paris, France
- Groupe Hospitalier Pitié Salpêtrière
-
Pontoise, France
- Centre Hospitalier Rene Dubos
-
Villeneuve Saint Georges, France
- CHI de Villeneuve
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- STEMI patient treated within the first 24 hours with primary PCI (with stent implantation)
- Age superior or equal to 18 years old
- Informed consent signed
- Patient volunteer to be submitted to the 1 year visit follow up and to the clinical exams during this visit
- Patient benefiting from French social health system
Exclusion Criteria:
- NONSTEMI patient with high troponin
- STEMI patient treated after the first 24 hours
- Stable / unstable angina or silent ischemia
- Cardiogenic shock
- Oral anticoagulation (Vitamin K Antagonists)
- Contraindication for PCI
- Age inferior to 18 years old
- Life expectancy inferior to 1 year
- Participation in another clinical trial
- No signed informed consent
- Patient not available for the 1 year visit follow up
- Pregnant women
- Known allergy to media contrast that can not be controlled by an adapted treatment
- Known allergy to cobalt chromium alloy
- Left ventricular ejection fraction lower than 30%
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
[*1] Genotype - Good responders to Clopidogrel
This group of patients is defined thanks to the DNA extracted from their saliva: [*1] genotype patients are good responders to clopidogrel
|
[*2] genotype with adapted thienopyridine treatment
This group of patients is defined thanks to the DNA extracted from their saliva: [*2] genotype patients are bad responders to clopidogrel and their thienopyridine treatment has been adapted
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
statistical difference in Death, MI and stent thrombosis between genetically resistant patients (*2 genotype) with adapted treatment and non resistant patients (*1 genotype)
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in MACCE between responder + compliant patients vs responders + non compliant patients vs non responder patients.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bernard Chevalier, Hôpital Privé Jacques Cartier
- Principal Investigator: Gilles Montalescot, Assistance Publique - Hôpitaux de Paris
- Principal Investigator: Loïc Belle, Centre Hospitalier de la Région Annecienne
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GIANT200905-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of